2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
Original-Research: Ikonisys SA - von Sphene Capital GmbH
Einstufung von Sphene Capital GmbH zu Ikonisys SA
Unternehmen: Ikonisys SA
ISIN: FR00140048X2
Anlass der Studie: Update Report
Empfehlung: Buy
seit: 09.02.2022
Kursziel: EUR 7,70 (unverändert)
Kursziel auf Sicht von: 24 Monate
Letzte Ratingänderung: -
Analyst: Peter Thilo Hasler, CEFA
Important client-win in Italy
After the first sale of the new-gen microscope, the Ikoniscope20, to one of the biggest genetic laboratories in Italy, we confirm our Buy rating for the shares of Ikonisys and our three-stage discounted cash flow entity model (primary valuation method) share price target of EUR 7.70.
Ikonisys announced the sale and installation of the Ikoniscope20 at Toma Advanced Biomedical Assays Spa ('TomaLab') in Busto Arsizio near Milan. TomaLab has been successfully validating the Ikoniscope20 for routine FISH testing in oncology, using several applications that span from lung cancer (oncoFISH ALK) to bladder cancer (oncoFISH bladder).
With revenues of more than EUR 20m and approximately 100 employees, TomaLab is one of the biggest accredited medical analysis laboratories in Italy, offering a full range of genetic diagnostic services in oncology, reproduction, ophthalmology, cardiology, and forensic genetics. The company operates specialised departments for clinical biochemistry and toxicology, microbiology and virology, pathological anatomy, cytogenetics and medical genetics.
According to Ikonisys, TomaLab will continue to collaborate on the development of novel applications for tests that will be of particular interest in the field of cancer diagnostics, especially regarding the Ikoniscope's ability to perform both FISH- and antibody-based tests. In addition, due to the particularly high level of qualification, TomaLab will act as a reference laboratory for Ikonisys. Potential clients of Ikonisys will be informed by TomaLab about the advantages and special characteristics of the Ikoniskope20. In our view this could significantly shorten the sales cycle for Ikonisys in the future.
Die vollständige Analyse können Sie hier downloaden: http://www.more-ir.de/d/23345.pdf
Kontakt für Rückfragen
Peter Thilo Hasler, CEFA
+49 (89) 74443558/ +49 (152) 31764553
peter-thilo.hasler@sphene-capital.de
-------------------übermittelt durch die EQS Group AG.-------------------
Für den Inhalt der Mitteilung bzw. Research ist alleine der Herausgeber bzw. Ersteller der Studie verantwortlich. Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
